All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-la-Neuve, BE and Noopur Raje, Massachusetts General Hospital, Boston, US. In this podcast, they discuss the topic: Managing infections with novel immunotherapies: Prevention, treatment, and impact on the quality of life of patients with multiple myeloma.
Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM
Raje and Delforge discuss the management of infections with novel immunotherapies, including: monoclonal antibodies, antivirals, risk of infection, intravenous immunoglobulin, and the impact of COVID-19. This podcast closely links to our latest editorial theme, in which the Multiple Myeloma Hub explores how to manage adverse events from novel agents, with our first article examining proteasome inhibitors and cardiovascular events.
Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Pieter...
My top 5 communications from the 18th IMW
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. He discussed the top five communications from the...
Subscribe to get the best content related to multiple myeloma delivered to your inbox